Aethlon Medical reported financial results for Q2 FY2025 ended September 30, 2024. Revenue remained at $0, while net loss decreased to $2.81 million from $3.03 million year-over-year. Operating expenses fell 8.6% to $2.90 million, driven by lower professional fees, partially offset by higher payroll costs.The company made progress on its cancer clinical trials, with two Australian hospitals now open for patient enrollment. In November, the first two patients at Royal Adelaide Hospital completed screening and advanced to the run-in period. Aethlon also received ethics approval for a trial site in India.Cash and equivalents stood at $6.86 million as of September 30, up from $5.44 million on March 31, bolstered by a $4.7 million public offering in May. However, management stated existing cash is insufficient to fund operations for 12 months, indicating additional financing will be required. The company continues to advance its Hemopurifier device for cancer and viral diseases.

Aethlon Medical reported financial results for Q2 FY2025 ended September 30, 2024. Revenue remained at $0, while net loss decreased to $2.81 million from $3.03 million year-over-year. Operating expenses fell 8.6% to $2.90 million, driven by lower professional fees, partially offset by higher payroll costs.The company made progress on its cancer clinical trials, with two Australian hospitals now open for patient enrollment. In November, the first two patients at Royal Adelaide Hospital completed screening and advanced to the run-in period. Aethlon also received ethics approval for a trial site in India.Cash and equivalents stood at $6.86 million as of September 30, up from $5.44 million on March 31, bolstered by a $4.7 million public offering in May. However, management stated existing cash is insufficient to fund operations for 12 months, indicating additional financing will be required. The company continues to advance its Hemopurifier device for cancer and viral diseases.